US4595689A
Expired / Lapsed
US
⏱️ 0.0 years remaining
4-(8-bromodibenz[b,f]oxepin-10-yl)-1,2,3,6-tetrahydro-1-methylpyridine and 4-(2-bromodibenzo[a,d]cyclophetatriene-11-yl)-1,2,3,6-tetrahydro-1-methylpyridine for dermal inflammation
Assignee: Hoffmann La Roche Inc
•
Filing: 1984-02-09
•
Granted: 1986-06-17
•
Expires: 2004-02-09
Abstract
Abstract A method of treating inflammation which comprises topically administering to the affected area a compound of the formula <IMAGE> or <IMAGE> or a pharmaceutically acceptable addition salt thereof, is described.
Inventors
- 👤 Alfred Boris
- 👤 Robert W. Guthrie
- 👤 Richard W. Kierstead
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-24 07:18
CPC Classifications
C; C07; C07D; C07D405/00; C07D405/02; C07D405/04; C07D211/00; C07D211/04; C07D211/68; C07D211/70
Claims Analysis
Total Claims: 5
Claim 1
Independent Claim
35 words
A method for treating dermal inflammation which comprises topically administering to the affected area an effective amount of a compound selected from the group consisting of 4-(8-bromodibenz[b,f]oxepin-10-yl)-1,2,3,6-tetrahydro-1-methylpyridine, 4-(2-bromodibenzo[a,d]cycloheptatriene-11-yl)-1,2,3,6-tetrahydro-1-methylpyridine or a pharmaceutically acceptable addition salt thereof.
Claim 2
Independent Claim
35 words
A method for treating dermal inflammation which comprises topically administering to the affected area an effective amount of a compound selected from the group consisting of 4-(8-bromodibenz[b,f]oxepin-10-yl)-1,2,3,6-tetrahydro-1-methylpyridine, 4-(2-bromodibenzo[a,d]cycloheptatriene-11-yl)-1,2,3,6-tetrahydro-1-methylpyridine or a pharmaceutically acceptable addition salt thereof.
Claim 3
Dependent Claim
12 words
The method in accordance with claim 1, wherein the compound is 4-(2-bromodibenzo[a,d]cycloheptatriene-11-yl)-1,2,3,6-tetrahydro-1-methylpyridine.
Claim 4
Dependent Claim
12 words
The method in accordance with claim 1 wherein the compound is 4-(8-bromodibenz[b,f]oxepin-10-yl)-1,2,3,6-tetrahydro-1-methylpyridine.
Claim 5
Dependent Claim
18 words
The method in accordance with claim 1, wherein the pharmaceutically acceptable addition salt is 4-(8-bromodibenz[b,f]oxepin-10-yl)-1,2,3,6-tetrahydro-1-methylpyridine, (Z)-2-butenedioate (1:1) salt.
References Cited (Backward Citations)
US3479356A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1989-06-16 | 1989-12-16 | 1990-06-17 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1993-06-16 | 1993-12-16 | 1994-06-17 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1997-06-16 | 1997-12-16 | 1998-06-17 | $7700.00 | Window Closed / Lapsed |